Back to resultsWeekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer
Primary Purpose
Ovarian Carcinoma, Primary Peritoneal Carcinoma
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Carboplatin
Docetaxel
Sponsored by
About this trial
This is an interventional treatment trial for Ovarian Carcinoma
Eligibility Criteria
Inclusion Criteria: Recurrent ovarian or peritoneal cancer Exclusion Criteria: No prior chemotherapy
Sites / Locations
- University of Wisconsin Hospital and Clinics
Outcomes
Primary Outcome Measures
Safety and Efficacy
Secondary Outcome Measures
QOL
Full Information
NCT ID
NCT00214058
First Posted
September 13, 2005
Last Updated
November 15, 2019
Sponsor
University of Wisconsin, Madison
Collaborators
Aventis Pharmaceuticals
1. Study Identification
Unique Protocol Identification Number
NCT00214058
Brief Title
Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer
Official Title
Phase II Evaluation of Weekly Docetaxel in Combination With Weekly Carboplatin in the Treatment of Recurrent Epithelial Ovarian Carcinoma
Study Type
Interventional
2. Study Status
Record Verification Date
June 2008
Overall Recruitment Status
Completed
Study Start Date
August 2002 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
February 2006 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Wisconsin, Madison
Collaborators
Aventis Pharmaceuticals
4. Oversight
5. Study Description
Brief Summary
The purpose of this study is to determine the safety and efficacy of this regimen in women with ovarian or peritoneal cancer
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ovarian Carcinoma, Primary Peritoneal Carcinoma
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
36 (false)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Carboplatin
Intervention Type
Drug
Intervention Name(s)
Docetaxel
Primary Outcome Measure Information:
Title
Safety and Efficacy
Secondary Outcome Measure Information:
Title
QOL
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Eligibility Criteria
Inclusion Criteria:
Recurrent ovarian or peritoneal cancer
Exclusion Criteria:
No prior chemotherapy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David M Kushner, MD
Organizational Affiliation
University of Wisconsin, Madison
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Wisconsin Hospital and Clinics
City
Madison
State/Province
Wisconsin
ZIP/Postal Code
53792
Country
United States
12. IPD Sharing Statement
Links:
URL
https://cancer.wisc.edu
Description
University of Wisconsin Carbone Cancer Center
Learn more about this trial
Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer
We'll reach out to this number within 24 hrs